CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Marks ‘Major Turning Point’ Through Kasa Wholefoods Division

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced that its food and beverage division, Kasa Wholefoods Company S.A.S., has completed its first purchase order, valued at approximately US$1.1 million. The order was for Importaciones y Asesorias Tropi S.A.S. (“Tropi”) as part of the sales agreement announced in July, and Flora expects Kasa to complete similar monthly deliveries moving forward. “We believe this initial sale demonstrates Flora’s ability to rapidly follow through on its commitments and marks a major turning point for our Kasa Wholefoods division. We expect this relationship with Tropi to generate significant revenue potential in both the short and long term as we build upon a relationship with the leading food and beverage distributor in Colombia,” said Jason Warnock, chief revenue officer of Flora. “Moving forward, we will work to increase monthly sales to our target of US$2M, including foraying into the newly permitted product category of cannabis-containing ingestible products that will offer increased wellness properties for end consumers.”

To view the full press release, visit https://cnw.fm/Lh8HT

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Announces Completion of First Canadian Keef Beverage Production Run

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), an emerging leader in innovative health and wellness beverages and products, has wrapped up the production of its first delivery of Keef cannabis-infused beverage to Canada. BevCanna is confident that the launch of its number-one selling product in the United States will establish the company as a leader in the Canadian cannabis-infused beverage sector. BVNNF’s Keef Brands has built an international reputation for its quality, and Canadian consumers have been waiting for the top-selling classic sodas to be available in their own country. BevCanna and Keef inked a bi-lateral partnership earlier this year for BevCanna to launch the Keef beverages in Canada. The agreement also enables BevCanna to leverage Keef’s extensive U.S. manufacturing and distribution network to launch its own line of products in the United States. “This inaugural run of Keef represents a significant milestone for BevCanna,” said BevCanna Enterprises president Melise Panetta in the press release. “We’re launching in multiple Canadian markets and are excited to be including this already well-known and loved cannabis brand among our first offerings. We expect that Keef will take a leadership position within the Canadian cannabis-infused beverage space.”

To view the full press release, visit https://cnw.fm/vygom

About BevCanna Enterprises Inc.

BevCanna Enterprises is a diversified health and wellness beverage and natural products company. BevCanna develops and manufactures a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, BevCanna owns a pristine alkaline spring water aquifer and a world-class, 40,000-square-foot, HACCP-certified manufacturing facility, with a bottling capacity of up to 210 million bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with number-one U.S. cannabis beverage company Keef Brands. For more information about the company, please visit www.BevCanna.com.

NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://cnw.fm/BVNNF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Senate Leaders Release Infrastructure Deal Seeking to Allow Studies Using Cannabis from Dispensaries

Earlier this week, Senate leaders released a bipartisan infrastructure legislation that includes provisions that permit researchers to conduct studies on the cannabis that consumers are purchasing from dispensaries in legal states. Prior to this, researchers were only allowed to conduct research on government-grown marijuana.

In addition, the legislation encourages states that have enacted marijuana legalization laws to educate individuals on impaired driving. The legislation also stipulates that the Health and Human Services Secretary and the Attorney General compile a report two years after the legislation’s enactment that would include recommendations on permitting researchers to access retail-level cannabis, which would allow them to conduct research on impaired driving.

In addition to this, the legislation notes that the report must include recommendations on creating a clearinghouse to distribute and collect strains and samples of cannabis for various research projects studying cannabis and products that contain cannabis that is available to consumers or patients on a retail basis in a legal state. It adds that researchers from states that are yet to legalize the herb should still be able to access dispensary products that are being sold in states that have ended marijuana prohibition.

Sen. John Hickenlooper, who argued that these changes were necessary to help promote research into impaired driving and establish a national standard for addressing the issue, sponsored the amendment that contained these reforms.

The legislation is to be introduced to the Senate in a few days. If approved, it would be reintroduced to the House floor for consideration before it is advanced to President Biden’s desk.

The legislation states that the marijuana research report must extensively examine federal regulatory and statutory barriers to studies on cannabis-impaired driving. The bill also comprises of a clause that would make it necessary for legal cannabis states to educate individuals on impaired driving and discourage it.

However, advocates are concerned with the language used because it ignores the fact that cannabis-impaired driving will occur, regardless of marijuana’s legal status, and targets legalized states. This does not mean that advocates aren’t supportive of measures to decrease impaired driving. They have also aired their concerns on the implication that legalizing marijuana grows the risk of individuals driving while under the influence of the herb. Research on the issue is yet to settle the matter.

Recently, a study that was promoted by the “National Institute of Justice” and funded by the federal government discovered that the amount of THC in an individual’s system after they consumed cannabis wasn’t an accurate predictor of impairment.

These attempts by federal legislators to enact some reforms to the existing prohibitive cannabis policies send signals to all marijuana industry players, including American Cannabis Partners, that a time is coming when major regulatory reforms will be implemented at the federal level, thereby putting an end to many of the contradictions inherent in federal law vs. state marijuana laws.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — What the Future Holds for Hemp-Sourced Cannabinoids

In the early 1970s, the federal government outlawed all cannabis cultivation, and failing to distinguish between hemp and its psychoactive cousin cannabis, declared it illegal to cultivate both cannabis and hemp. These policies held for decades, and while the illicit market continued supplying cannabis, hemp nearly faded into obscurity. In 2014, Congress passed a farm bill that allowed state agriculture departments and universities to grow hemp in pilot programs as long as their home states permitted it.

Four years later, the 2018 farm gill removed hemp from the list of controlled substances, allowing the cultivation, processing and sale of hemp and hemp derivatives. Just a few years later, America’s young hemp industry has blossomed, partly driven by the explosive demand for cannabinoids, CBD in particular.

Cannabinoids are chemical compounds produced by plants of the cannabis sativa species, which includes hemp and cannabis. Hemp has less than 0.3% THC, the main psychoactive compound in cannabis, hence hemp products will not intoxicate you.

Said to be filled with potent medicinal properties, CBD has made hemp extremely valuable. The CBD pace has advanced rather quickly, and some have called the industry a Wild West where hype has far outpaced science. Consequently, the FDA has warned several companies against marketing CBD products as over the counter medicines and raised concerns about adding CBD to ingestible products such as foods, beverages, and dietary supplements. Still, nearly every states has passed some form of hemp legislation and allows the use of hemp and its derivatives in a variety of consumer products, including ingestible products and pet products.

Other minor cannabinoids, including cannabigerol (“CBG”), delta-8 THC and cannabinol (“CBN”), have been subject to increasing attention. However, these minor cannabinoids are relatively unknown and make up a very small segment of the hemp industry. They still have plenty of regulatory hurdles to clear, let alone gaining the high level of market visibility that CBD has achieved within the past five years. Since these minor cannabinoids have barely been subject to scientific research and clinical studies, policymakers still do not understand them or what they can do.

In fact, we do not know a lot about most of the approximately 100 cannabinoids hemp produces. But based on how cannabidiol fared, we can assume that these cannabinoids will also go through a similar process. Increasing popularity will attract more sellers to the market, plenty of them unscrupulous. We may even see companies advertising these cannabinoids as miracle cures for certain diseases, much like some companies have done with CBD. However, the FDA has been quick to shut down such claims and offer guidance on CBD, and we can assume the federal agency will do the same with the larger hemp-sourced cannabinoid sector.

Sellers are constantly coming up with new CBD products, forcing federal and regulators to constantly redefine what is legal and what isn’t. Some states may allow cannabinoid-infused transdermal patches and CBD flower while others may not. Meanwhile, the FDA will continue to provide guidance on cannabinoids and how they can and cannot be used in the absence of a federal comprehensive regulatory structure.

At the moment, cannabis companies that are interested in different cannabinoids, such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), are working within the existing regulatory framework to manufacture premium products aimed at addressing the needs of their customers.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Patients with High-Grade Gliomas Register Improved Quality of Life after Using Medical Marijuana

The past few decades have seen cannabis progress from an intensely policed drug with no perceived medical applications to a “miracle drug” with a plethora of health benefits. Anecdotal reports and preliminary studies have found it to be effective against, among other things, chronic pain, anxiety insomnia, nausea and vomiting, which are incidentally the symptoms often endured by individuals suffering from cancer who are undergoing chemotherapy. Thanks to restrictive cannabis policies, few researchers have been able to conclusively study how cannabis affects the quality of life of cancer patients.

However, a recent study published in “Frontiers in Oncology” sought to answer this question in the midst of loosening cannabis restrictions. Researchers conducted a randomized, phase 2 trial that compared the effect of two different ratios of oral medical cannabis oil in patients with inoperable or recurrent gliomas. They discovered that a nightly dose of medical marijuana led to improved symptoms that determine quality of life, such as sleep.

The study, which is one of the few of its kind, had 88 participating patients with the average age of 53.3 years. Most of the patients (95.2%) were white with approximately one- half of them (49.4%) being women. The patients randomly received medical cannabis with either 1:1 ratio of THC to CBD (4.6 mg/ml:4.8 mg/ml) or a 4:1 ratio of THC to CBD (15 mg/ml:3.8mg/ml).The researchers then used a paired t-test for the Functional Assessment of Cancer Therapy-Brain (FACT-Br) to study quality of life changes from week 1 to week 12.

Fifty-three patients also had MRIs at the start of the study and at week 12 to determine disease status. The researchers found that the daily dose of medical cannabis resulted in significant improvements in the physical and functional domains as well as sleep with the 1:1 medical cannabis being more effective that the 4:1 ratio. However, there was no significant difference between the two ratios in terms of disease status: 11% of the 53 patients experienced a reduction in disease status, 34% remained stable and 10% had progressive disease.

While there is usually a risk of adverse reactions with such studies, the researchers say the participants tolerated both medical cannabis ratios quite well. Still, they did experience the common side effects of cannabis consumption; drowsiness (7%), dizziness at night (10%), tiredness at night (11%) and dry mouth (13%). The researchers concluded that based on their data, cannabis, especially the 1:1 THC to CBD ratio, could help patients with high grade gliomas have a higher quality of life.

THC and CBD are the most abundant of the cannabinoids in marijuana, but the plant actually contains dozens more, and companies such as InMed Pharmaceuticals Inc. (NASDAQ: INM) are focused on unlocking the therapeutic benefits of those lesser-known cannabinoids such as CBN, which have proved in preliminary research to possess greater potential as medicines when compared to CBD and THC.

NOTE TO INVESTORS: The latest news and updates relating to InMed Pharmaceuticals Inc. (NASDAQ: INM) are available in the company’s newsroom at https://cnw.fm/INM

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Why Investors Interested in Cannabis Should Expect a Big Stock Surge

At the moment, more than 100 million residents in the United States live in a state that has legalized recreational cannabis, with a whopping 95% living in a state with a legal medical cannabis system in place. Cannabis multistate operators are readying themselves for the next huge stock increase, which is expected to happen even without a change in federal legislations.

Marijuana is fast closing the revenue gap, especially with the emergence of profitability, after the huge infrastructure spending that began in 2018 and 2019. Trading indexes show favorable valuations throughout this season, despite the imminent federal legislative gridlock.

Marijuana revenues in the United States increased significantly between 2014 and 2020, moving from $1.9 billion to $17.5 billion, even without the enactment of federal legislations such as the SAFE Banking Act. Recent forecasts from “Forbes” show that by 2025, the U.S. marijuana market will have reached $43 billion, which is quite a jump from the $29 billion prediction from a few months ago.

With more states across the country legalizing the herb for recreational and/or medicinal use, 2021 is set to be a good year, with the cannabis market expected to see an even larger increase in the coming year. Additionally, as more demographics such as seniors get on board with marijuana therapies, the industry expands faster and grows even stronger.

The quality of companies now operating in the marijuana market is considerably different from companies that were operating in the market in 2015 when the U.S. Marijuana Index begun. Small companies are now focused on profit making, which entails starving multistate operators of capital markets with profitability also being the main objective of larger and better-developed multistate operators.

Infrastructure building as well as mergers and acquisitions have also increased substantially, with both global and U.S. capital markets responding to this by increasing their cannabis services. The United States is receiving the biggest benefit of private equity financing because of the increased fundamentals of cannabis companies and the huge revenue stream that’s gaining momentum.

Whether we like it or not, the profitability model brought by marijuana federal legalization in Canada is here to stay. Despite most monies being injected into companies in the United States, investing in profitable operations is still the main aim, especially as infrastructure and M&A investments are expected to increase annually in this particular market.

Until federal regulations catch up to consumer preferences, marijuana sales will continue increasing, more states will legalize the herb, and companies will continue to hit record highs.

When you see industry players such as Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) report nearly 200 people on their payroll, it appears to be a clear sign that the sector is growing and things are likely to keep looking up for years to come.

NOTE TO INVESTORS: The latest news and updates relating to Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) are available in the company’s newsroom at https://cnw.fm/CHALF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) to Host 1H 2021 Earnings Call

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that it will host its first-half 2021 earnings call following the release of its first-half 2021 financial results. The webcast is scheduled to be held at 4:30 p.m. ET on Thursday, Aug. 19, 2021. FLGC management will deliver financial results, operational updates, as well as provide comments on recent growth and M&A initiatives announced in the period since the company listed its shares on the Nasdaq Capital Market on May 11, 2021. Following the presentation, Flora will offer analysts, media and investors the opportunity to ask questions in a question-and-answer session. Interested parties may join the live webcast by visiting https://cnw.fm/89ocu. In addition, a replay of the call will be available until Sept. 3, 2021, by dialing 1-844-512-2921 (Canada/USA) or 1-412-317-6671 (international) and entering access code: 13722364.

To view the full press release, visit https://cnw.fm/O1tbc

About Flora Growth Corp.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals

Lexaria Bioscience Corp. (NASDAQ: LEXX) is constantly collaborating with research institutions and businesses to identify new ways to innovate and improve its DehydraTECH(TM) drug-delivery technology. DehydraTECH is already being monetized through commercial use, and the company is utilizing advanced 2.0 formulations in ongoing human studies. A recent article discusses Lexaria’s move to consolidate the trading of its shares solely on the Nasdaq, and resulting advantages to the company and its shareholders. “Since it was listed back in January 2021, a substantial fraction of its shareholders moved onto this exchange. To them, it offered more liquidity than ever before, and to Lexaria, it presented an opportunity to realize savings in fees and managerial time,” the article reads. “The company’s management intends to direct the cost savings resulting from this move to its applied research and development programs, which would further advance the company’s business. Just earlier this year, Lexaria’s HYPER-A21-1 study resulted in the inclusion of three new DehydraTECH 2.0 formulation variations that would enable cannabidiol (‘CBD’) delivery performance enhancements as well as pharmacokinetic optimization. With more funding for such research, Lexaria is well-positioned to achieve even better results and better outcomes for its drug-delivery goals.”

To view the full article, visit https://cnw.fm/1Hr3A

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes. It is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Green Hygienics Holdings Inc. (GRYN) Stands Distinct in Industrial Hemp Sector

Green Hygienics Holdings (OTCQB: GRYN) is enhancing its corporate responsibility and sustainability goals to empower environmental progress. The company plans to incorporate systemic environmental, social and governance (“ESG”) factors into business planning aimed at serving the needs of investors and stakeholders who value the importance of ESG reporting. “With the help of KERAMIDA Inc., a premier sustainability consulting firm, Green Hygienics is developing an ESG report using the Sustainability Accounting Standards Board (‘SASB’), maintained by the Value Reporting Foundation. Sustainability and ESG are an integral part of the company’s value system,” reads a recent article. Green Hygienics is the first industrial hemp company to undertake an ESG report, reflecting a proactive approach to move ahead of future government mandates. Developing an ESG report and following through on its guidelines is likely to further cement Green Hygienics’ position in the market, as well as influence positive investor interest and growth opportunities.

To view the full article, visit https://cnw.fm/LSJx6

About Green Hygienics Holdings Inc.

Green Hygienics Holdings is a California-based, innovative, technology-driven enterprise focused on the high-standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids. The company’s corporate mission is to adhere to the highest standards of operations in consistently delivering safe and premium-quality products to consumers as well as to partner with CPG (consumer packaged goods) and pharmaceutical companies. Hygienics is the science of preserving and promoting the health of individuals, communities and the planet. For more information about the company, visit www.GreenHygienics.com.

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://cnw.fm/GRYN

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — California Senator Asks Feds to Clarify Medical Cannabis Use Within Hospitals

The state legal cannabis industry can be a frustrating and confusing space. Despite the fact that more than 30 states have legalized medical marijuana, federal law still considers cannabis a Schedule I controlled substance with no medical applications. So while on one end nearly 5.5 million patients are using medical cannabis to alleviate a variety of medical issues, the federal government outlaws the controversial drug and requires federal agencies and institutions that rely on federal funding to follow its marijuana policies.

This has been a significant issue for the past few years, with businesses and individuals finding themselves penalized by the federal government for acts that are considered legal in their home states. In fact, this confusion led California Gov. Gavin Newsom to veto a bill that would have allowed health institutions to allow cannabis use as he was under the impression that this would jeopardize their federal funding.

In that vein, a California senator has sent a request asking the head of the U.S. Department of Health and Human Services (“HHS”) to clarify whether hospitals and healthcare institutions in states with legal marijuana markets can allow terminally ill patients to use medical cannabis without risking their federal funding. Since the federally funded institutions are required to abide by federal policies, it makes sense that healthcare institutions would be wary of recommending medical marijuana to their patients.

Sent by Senator Ben Huesco to HHS Secretary Xavier Becerra and Centers of Medicare and Medicaid Services (“CMS”) Administrator Chiquita Brooks LaSure, the letter asks the federal officials to lay out the possible implications if health facilities start permitting marijuana consumption. Senator Huesco has also filed an almost identical version of the bill, which has already advanced in the Senate as well as one Assembly committee and is now pending action on the Assembly floor.

Dubbed Ryan’s Law, the legislation would require hospitals and some healthcare facilities in California to allow terminally ill patients to use medical cannabis for treatment and pain relief. While hospitals that receive CMS accreditation currently do not allow this due to fear of federal reprisals, Huesco says a letter sent to his office by the CMS states no federal regulations specifically address this issue, and the agency isn’t aware of any hospital that has had its funding pulled due to medical marijuana.

Still, most hospitals, and even lawmakers, have been under the impression that hospitals couldn’t allow medical cannabis use, the letter notes. As such, providing clarification on whether or not Medicare/Medicaid providers will lose federal reimbursement for allowing medical cannabis on site would be significantly helpful to the patients who need medical cannabis and hospitals.

If the clarification is provided that patients can use medical marijuana in hospitals located in states with medical cannabis laws, one of the many ambiguities that the entire cannabis industry, including Sonoma Biologics Corp., faces would have been removed.

NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.